OncoMatch/Clinical Trials/NCT07050043
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
Is NCT07050043 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Nivolumab 40mg and Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel for nsclc (non-small cell lung carcinoma).
Treatment: Nivolumab 40mg · Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel — This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation (wild-type)
Presence of EGFR, ALK , ROS1 mutation(s) [excluded]
Required: ALK mutation (wild-type)
Presence of EGFR, ALK , ROS1 mutation(s) [excluded]
Required: ROS1 mutation (wild-type)
Presence of EGFR, ALK , ROS1 mutation(s) [excluded]
Required: PD-L1 (CD274) expression (documented)
with documented PD-L1 expression
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior treatment with any anti-PD-1, anti-PD-L1 or any other antibody targeting an immune checkpoint
Lab requirements
Blood counts
adequate organ function including the following laboratory values at the screening visit as per Table 2
Kidney function
adequate organ function including the following laboratory values at the screening visit as per Table 2
Liver function
adequate organ function including the following laboratory values at the screening visit as per Table 2
Participants must have adequate organ function including the following laboratory values at the screening visit as per Table 2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify